Noida Chronicle

Cholestatic Liver Disease-associated Pruritus Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – GSK, Cara Therapeutics

 Breaking News
  • No posts were found

Cholestatic Liver Disease-associated Pruritus Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – GSK, Cara Therapeutics

March 14
01:13 2023
Cholestatic Liver Disease-associated Pruritus Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies -  GSK, Cara Therapeutics

DelveInsight’s “Cholestatic Liver Disease-associated Pruritus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cholestatic Liver Disease-associated Pruritus, historical and forecasted epidemiology as well as the Cholestatic Liver Disease-associated Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cholestatic Liver Disease-associated Pruritus Overview

Pruritus is a debilitating symptom of various cholestatic disorders, including primary biliary cholangitis, primary sclerosing cholangitis and inherited progressive familial intrahepatic cholestasis. Cholestatic Liver Disease-associated Pruritus causes a sensation of itch because of any liver disease.

Some of the key facts of the Cholestatic Liver Disease-associated Pruritus Market Report:

  • Cholestatic Liver Disease-associated Pruritus market size is anticipated to increase with a significant CAGR during the study period 2019-32.
  • According to a study by Kido-Nakahara et al. , among 216 patients with chronic liver disease, 41.2% suffered from pruritus.
  • Cholestatic Liver Disease-associated Pruritus key companies such as, GSK, Cara Therapeutics, Regeneron Pharmaceuticals, Avior Bio and others are working towards developing the Cholestatic Liver Disease-associated Pruritus drugs.
  • Cholestatic Liver Disease-associated Pruritus emerging therapies like Linerixibat, CR845, Dupilumab, AV104 among others are expected to change the dynamics of the Cholestatic Liver Disease-associated Pruritus market.

Request a sample for the Cholestatic Liver Disease-associated Pruritus Market Report

Key benefits of the Cholestatic Liver Disease-associated Pruritus Market report:

  1. Cholestatic Liver Disease-associated Pruritus market report covers a descriptive overview and comprehensive insight of the Cholestatic Liver Disease-associated Pruritus Epidemiology and Cholestatic Liver Disease-associated Pruritus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Cholestatic Liver Disease-associated Pruritus market report provides insights on the current and emerging therapies.
  3. Cholestatic Liver Disease-associated Pruritus market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Cholestatic Liver Disease-associated Pruritus market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Cholestatic Liver Disease-associated Pruritus market.

The Report Covers the Cholestatic Liver Disease-associated Pruritus Epidemiology, Segmented by –

  • Total Incident Cases of Cholestatic Liver Disease-associated Pruritus in the 7MM (2019–2032)
  • Gender-specific Cases of Cholestatic Liver Disease-associated Pruritus in the 7MM (2019–2032)
  • Age-specific Cases of Cholestatic Liver Disease-associated Pruritus in the 7MM (2019–2032)
  • Mutation-specific Cases of Cholestatic Liver Disease-associated Pruritus in the 7MM (2019–2032)
  • Treated Cases of Cholestatic Liver Disease-associated Pruritus by the line of therapies in the 7MM (2019–2032)
  • Treated Cases of Cholestatic Liver Disease-associated Pruritus by status in the 7MM (2019–2032)

Cholestatic Liver Disease-associated Pruritus Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cholestatic Liver Disease-associated Pruritus market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Cholestatic Liver Disease-associated Pruritus market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Cholestatic Liver Disease-associated Pruritus Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Liver Disease-associated Pruritus market or expected to be launched during the study period. The analysis covers the Cholestatic Liver Disease-associated Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Cholestatic Liver Disease-associated Pruritus Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn more by requesting for sample @ Cholestatic Liver Disease-associated Pruritus Market Landscape 

Cholestatic Liver Disease-associated Pruritus Pipeline Therapies and Key Companies 

  • Linerixibat: GSK
  • CR845: Cara Therapeutics
  • Dupilumab: Regeneron Pharmaceuticals
  • AV104: Avior Bio

Table of Contents

1. Cholestatic Liver Disease-associated Pruritus Market Report Introduction

2. Executive Summary for Cholestatic Liver Disease-associated Pruritus

3. SWOT analysis of Cholestatic Liver Disease-associated Pruritus

4. Cholestatic Liver Disease-associated Pruritus Patient Share (%) Overview at a Glance

5. Cholestatic Liver Disease-associated Pruritus Market Overview at a Glance

6. Cholestatic Liver Disease-associated Pruritus Disease Background and Overview

7. Cholestatic Liver Disease-associated Pruritus Epidemiology and Patient Population

8. Country-Specific Patient Population of Cholestatic Liver Disease-associated Pruritus 

9. Cholestatic Liver Disease-associated Pruritus Current Treatment and Medical Practices

10. Cholestatic Liver Disease-associated Pruritus Unmet Needs

11. Cholestatic Liver Disease-associated Pruritus Emerging Therapies

12. Cholestatic Liver Disease-associated Pruritus Market Outlook

13. Country-Wise Cholestatic Liver Disease-associated Pruritus Market Analysis (2019–2032)

14. Cholestatic Liver Disease-associated Pruritus Market Access and Reimbursement of Therapies

15. Cholestatic Liver Disease-associated Pruritus Market drivers

16. Cholestatic Liver Disease-associated Pruritus Market barriers

17.  Cholestatic Liver Disease-associated Pruritus Appendix

18. Cholestatic Liver Disease-associated Pruritus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Cholestatic Liver Disease-associated Pruritus Pipeline 

“Cholestatic Liver Disease-associated Pruritus Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cholestatic Liver Disease-associated Pruritus market. A detailed picture of the Cholestatic Liver Disease-associated Pruritus pipeline landscape is provided, which includes the disease overview and Cholestatic Liver Disease-associated Pruritus treatment guidelines.

Cholestatic Liver Disease-associated Pruritus Epidemiology

DelveInsight’s ‘Cholestatic Liver Disease-associated Pruritus Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Cholestatic Liver Disease-associated Pruritus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com